India’s Parry Nutraceuticals Gets USFDA Approval

Based in India’s southern state of Tamil Nadu, Parry Nutraceuticals received the U.S. Food and Drug Administration approval for its India facility for organic micro-algae cultivation and processing.

Business head, Parry Nutraceuticals, Muthu Murugappan said that some of the products that they planned to bring to market over the next two years include Organic Chlorella, Spirulina Granules, CO2 Extracted Lutein and Algal Beta Glucan. New areas currently under development include vegan algal proteins, chlorophyll and algae  omega-3s, reports Outlook.

Parry Nutraceuticals Logo

Valensa International, based in Florida, which specializes in the development of condition-specific nutraceuticals such as joint, eye and cardio-vascular health issues, is a wholly owned subsidiary of Parry.

Be Sociable, Share!
Posted on by Gunjan Bagla
Gunjan Bagla
California-based management consultant Gunjan Bagla runs Amritt, a consulting firm helping American companies to succeed in India. Amritt is the trusted advisor for India market research, India business development, India market entry, Global Engineering, Global Technology Scouting, India R&D and Open Innovation. Gunjan is author of "Business in 21st Century India: How to Profit Today from Tomorrow’s Most Exciting Market" (Hachette Book Group, 2008), Amazon's top rated title on the subject. He has appeared as the India Expert on BBC Television, Bloomberg TV, Fox Cable Business and has been quoted in the New York Times, the Los Angeles Times, the Hollywood Reporter and Business Week for his expertise on India.


There are no comments yet...

Kick things off by filling out the form below.

Leave a Comment